Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Garfall, Alfred L.

Nooka, Ajay K.

van de Donk, Niels W. C. J.

Moreau, Philippe

Bhutani, Manisha

Oriol, Albert

Martin, Thomas G.

Rosinol, Laura

Mateos, Maria-Victoria

Bahlis, Nizar J.

Popat, Rakesh

Besemer, Britta

Martinez-Lopez, Joaquin

Krishnan, Amrita Y.

Delforge, Michel

Huang, Lin

Vishwamitra, Deeksha

Stephenson, Tara

Chastain, Katherine

Sidana, Surbhi

机构：

[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[3] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[4] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[5] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[6] Hosp Badalona Germans Trias & Pujol, Inst Catal Oncol, Badalona, Spain

[7] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[10] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Centro Invest Canc IBMCC USAL, CSIC, Salamanca, Spain

[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[12] Univ Coll London Hosp, NHS Fdn Trust, London, England

[13] Univ Hosp Tubingen, Tubingen, Germany

[14] Hosp 12 Octubre, Hematol, Madrid, Spain

[15] City Hope Comprehens Canc Ctr, Duarte, CA USA

[16] Univ Leuven, Leuven, Belgium

[17] Johnson & Johnson Innovat Med, Spring House, PA USA

[18] Johnson & Johnson Innovat Med, Raritan, NJ USA

[19] Stanford Univ, Sch Med, Stanford, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7540

引用

页数：1

共 50 条

[41] Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Lin, Yi
Raje, Noopur S.
Berdeja, Jesus G.
Siegel, David S.
Jagannath, Sundar
Madduri, Deepu
Liedtke, Michaela
Rosenblatt, Jacalyn
Maus, Marcela V.
Massaro, Monica
Petrocca, Fabio
Yeri, Ashish
Finney, Olivia
Caia, Andrea
Yang, Zhihong
Martin, Nathan
Campbell, Timothy B.
Rytlewski, Julie
Fuller, Jaymes
Hege, Kristen
Munshi, Nikhil C.
Kochenderfer, James N.
NATURE MEDICINE, 2023, 29 (09) : 2286 - +
[42] Plateau phase in multiple myeloma: An analysis of long-term follow-up of 432 patients
Oivanen, TM
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 92 (04) : 834 - 839
[43] Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Yi Lin
Noopur S. Raje
Jesús G. Berdeja
David S. Siegel
Sundar Jagannath
Deepu Madduri
Michaela Liedtke
Jacalyn Rosenblatt
Marcela V. Maus
Monica Massaro
Fabio Petrocca
Ashish Yeri
Olivia Finney
Andrea Caia
Zhihong Yang
Nathan Martin
Timothy B. Campbell
Julie Rytlewski
Jaymes Fuller
Kristen Hege
Nikhil C. Munshi
James N. Kochenderfer
Nature Medicine, 2023, 29 : 2286 - 2294
[44] Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
Mateos, Maria-Victoria
Chari, Ajai
Usmani, Saad
Goldschmidt, Hartmut
Weisel, Katja
Qi, Keqin
Londhe, Anil
Nair, Sandhya
Lin, Xiwu
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S192 - S193
[45] Talquetamab (tal) plus Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up
Cohen, Yael
Magen, Hila
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Ocio, Enrique
Yoon, Sung-Soo
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Quijano Carde, Natalia
Krevvata, Maria
Peterson, Michelle
Scott, Emma
Hilder, Brandi
Vanak, Jill
Banerjee, Arnob
Oriol, Albert
Morillo, Daniel
Mateos Manteca, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S2 - S3
[46] Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial
S Ailawadhi
J R Mikhael
B R LaPlant
K M Laumann
S Kumar
V Roy
D Dingli
P L Bergsagel
F K Buadi
S V Rajkumar
R Fonseca
M A Gertz
P Kapoor
T Sher
S R Hayman
A K Stewart
A Dispenzieri
R A Kyle
W I Gonsalves
C B Reeder
Y Lin
R S Go
N Leung
T Kourelis
J A Lust
S J Russell
A A Chanan-Khan
M Q Lacy
Leukemia, 2018, 32 : 719 - 728
[47] SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL
Richardson, P.
Siegel, D.
Vij, R.
Hofmeister, C.
Baz, R.
Jagannath, S.
Chen, C.
Lonial, S.
Jakubowiak, A.
Bahlis, N.
Song, K.
Belch, A.
Raje, N.
Shustik, C.
Lentzsch, S.
Chen, M.
Zaki, M.
Anderson, K.
HAEMATOLOGICA, 2013, 98 : 321 - 321
[48] LONG-TERM FOLLOW-UP AND THERAPY IN MULTIPLE MYELOMA
VELEZGAR.E
MALDONADO, N
CANCER, 1971, 27 (01) : 44 - +
[49] Long-Term Follow-up of Multiple Myeloma Patients Treated by VELCADE
Michallet, M.
Sobh, M.
Le, Q. H.
Barraco, F.
Dumontet, C.
Plesa, C.
Chelghoum, Y.
Cannas, G.
Virelizier, E. N.
Thomas, S.
Praire, A.
Nicolini, F. E.
Troncy, J.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S11 - S11
[50] LONG-TERM FOLLOW-UP OF MULTIPLE MYELOMA PATIENTS TREATED BY VELCADE
Michallet, M.
Sobh, M.
Le, Q. -H.
Barraco, F.
Nicolini, F. E.
Dumontet, C.
Chelghoum, Y.
Thomas, X.
Cannas, G.
Nicolas-Virelizier, E.
Plesa, N.
Ducastelle, S.
Troncy, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 618 - 619

← 1 2 3 4 5 →